이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Dynavax Technologies 관리
관리 기준 확인 4/4
Dynavax Technologies' CEO는 Ryan Spencer, Dec2019 에 임명되었습니다 의 임기는 4.67 년입니다. 총 연간 보상은 $ 5.81M, 13.1% 로 구성됩니다. 13.1% 급여 및 86.9% 보너스(회사 주식 및 옵션 포함). 는 $ 2.61M 가치에 해당하는 회사 주식의 0.18% 직접 소유합니다. 2.61M. 경영진과 이사회의 평균 재임 기간은 각각 3.6 년과 6.2 년입니다.
주요 정보
Ryan Spencer
최고 경영자
US$5.8m
총 보상
| CEO 급여 비율 | 13.1% |
| CEO 임기 | 4.8yrs |
| CEO 소유권 | 0.2% |
| 경영진 평균 재임 기간 | 3.7yrs |
| 이사회 평균 재임 기간 | 6.3yrs |
최근 관리 업데이트
Recent updates
Dynavax Technologies: Slow And Steady Wins The Race
Sep 05Dynavax Technologies: A Two Trick Pony Operating With A Single Trick
Aug 23Some May Be Optimistic About Dynavax Technologies' (NASDAQ:DVAX) Earnings
Aug 14
Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?
Jul 12Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S
May 22Dynavax: HEPLISAV-B Growth Up, Pipeline Uncertain
May 10Dynavax: Holding Firm Despite Its Missing Cash Cow
Mar 23Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Mar 06Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry
Jan 31These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely
Aug 02Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet
Jun 02We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease
May 03Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly
Jan 16Clover, Dynavax COVID-19 vaccine gets EU GMP certificate
Sep 20Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Sep 12The Alphavaxers: Dynavax And Novavax, 2 Quarters On
Aug 22Dynavax up 8% after raising full-year guidance for key adjuvant product, Q2 beats
Aug 04Are Investors Undervaluing Dynavax Technologies Corporation (NASDAQ:DVAX) By 41%?
Jun 03Dynavax: Evolving Endemic Situation Adds To Its Risk
May 23Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest
May 12Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt
May 10Dynavax Technologies: Full Speed Ahead
Mar 01Here's Why Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt Responsibly
Jan 28Dynavax: A Coronavirus Growth Story
Jan 17Is Dynavax Technologies Corporation (NASDAQ:DVAX) Expensive For A Reason? A Look At Its Intrinsic Value
Nov 18The Momentum Investor: Spotlight On Dynavax Technologies
Oct 25Dynavax And TLR Biology: Long-Delayed But Outstanding Success
Oct 16These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Reasonably Well
Oct 02CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$17m |
| Mar 31 2024 | n/a | n/a | US$9m |
| Dec 31 2023 | US$6m | US$760k | -US$6m |
| Sep 30 2023 | n/a | n/a | US$61m |
| Jun 30 2023 | n/a | n/a | US$111m |
| Mar 31 2023 | n/a | n/a | US$236m |
| Dec 31 2022 | US$6m | US$695k | US$293m |
| Sep 30 2022 | n/a | n/a | US$320m |
| Jun 30 2022 | n/a | n/a | US$228m |
| Mar 31 2022 | n/a | n/a | US$104m |
| Dec 31 2021 | US$5m | US$600k | US$72m |
| Sep 30 2021 | n/a | n/a | -US$39m |
| Jun 30 2021 | n/a | n/a | -US$6m |
| Mar 31 2021 | n/a | n/a | -US$62m |
| Dec 31 2020 | US$2m | US$515k | -US$75m |
| Sep 30 2020 | n/a | n/a | -US$97m |
| Jun 30 2020 | n/a | n/a | -US$138m |
| Mar 31 2020 | n/a | n/a | -US$129m |
| Dec 31 2019 | US$3m | US$391k | -US$156m |
보상 대 시장: Ryan 의 총 보상 ($USD 5.81M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 5.64M ).
보상과 수익: Ryan 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Ryan Spencer (46 yo)
4.8yrs
테뉴어
US$5,810,736
보상
Mr. Ryan Spencer serves as Independent Director at Cidara Therapeutics, Inc. from April 24, 2024. He serves as the Chief Executive Officer and Director of Dynavax Technologies Corporation since December 16...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO & Director | 4.8yrs | US$5.81m | 0.18% $ 2.5m | |
| President & COO | 11.5yrs | US$2.99m | 0.024% $ 351.3k | |
| Senior VP & CFO | 3.5yrs | US$2.07m | 0.0059% $ 84.6k | |
| Chief Medical Officer and Senior VP of Clinical Development | 11.2yrs | US$1.88m | 0.049% $ 706.9k | |
| Chief Accounting Officer & Controller | 4.3yrs | 데이터 없음 | 데이터 없음 | |
| Senior VP & Chief Human Resources Officer | 5.7yrs | 데이터 없음 | 데이터 없음 | |
| VP of Investor Relations & Corporate Communications | 1.7yrs | 데이터 없음 | 데이터 없음 | |
| Senior VP & General Counsel | 3.3yrs | 데이터 없음 | 데이터 없음 | |
| Senior VP & Chief Commercial Officer | no data | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Vaccine Research | 3.6yrs | 데이터 없음 | 데이터 없음 | |
| VP, Site Head & MD for Dynavax GmbH | 3.7yrs | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Technical Operations | 3.7yrs | 데이터 없음 | 데이터 없음 |
3.7yrs
평균 재임 기간
59.5yo
평균 연령
경험이 풍부한 관리: DVAX 의 관리팀은 경험 ( 3.6 년 평균 재직 기간)으로 간주됩니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO & Director | 4.8yrs | US$5.81m | 0.18% $ 2.5m | |
| Independent Director | 18.1yrs | US$298.73k | 0.021% $ 305.0k | |
| Independent Director | 14.2yrs | US$290.73k | 0.0011% $ 16.4k | |
| Independent Director | 14.8yrs | US$278.73k | 0.016% $ 229.2k | |
| Member of Scientific Advisory Board | 1.7yrs | US$1.83m | 데이터 없음 | |
| Member of Scientific Advisory Board | 6.3yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 4.2yrs | US$293.73k | 0% $ 0 | |
| Member of Scientific Advisory Board | 6.3yrs | US$20.00k | 데이터 없음 | |
| Independent Chairman of the Board | 2.9yrs | US$323.73k | 0% $ 0 | |
| Member of Scientific Advisory Board | 6.3yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 6.3yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 6.3yrs | 데이터 없음 | 데이터 없음 |
6.3yrs
평균 재임 기간
73.5yo
평균 연령
경험이 풍부한 이사회: DVAX 의 이사회는 경험(평균 재직 기간 6.2 년)으로 간주됩니다.